Dhaka, March 28 -- The High Court has questioned the inaction and failure of the government bodies concerned and other respondents to prevent money laundering involved transferring 60 per cent shares of Novartis Bangladesh Limited.

It has issued a rule upon the respondents to explain in four weeks as to why the failure and inaction to prevent money laundering involved with the overvaluation of share price by Radiant Pharmaceuticals Limited manipulating the market real value of the shares in the acquisition of majority shares of the Novartis Bangladesh Limited should not be declared illegal.

In the rule, the HC also asked the respondents to explain as to why they should not be directed to take effective steps, including but not limited t...